Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

By F. van Goor, Sabine Hadida, P. Grootenhuis, B. Burton, Dong Cao, Tim Neuberger, A. Turnbull, Ashvani K. Singh, J. Joubran, Anna R. Hazlewood and 11 more. Proceedings of the National Academy of Sciences of the United States of America, 2009

1,234 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/b3c173c25042844aa15b8077e977bcdae359120e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. F. van Goor
2. Sabine Hadida
3. P. Grootenhuis
4. B. Burton
5. J. Stack
6. W. Fokkens
7. K. Straley
8. C. Decker

Citations in the corpus

• SLC Transporters as Therapeutic Targets: Emerging Opportunities (2015, neutral): “Ivacaftor acts as a potentiator; it increases the activity of CFTR-G551D that is already present on the plasma membrane, by increasing the probability of the open state of the CFTR channel 82 .”
• European Position Paper on Rhinosinusitis and Nasal Polyps 2020. (2020, background): “Dysbiosis is a term indicating microbial imbalance and some evidence suggests that it is associated with the sinonasal microbiome of CRS patients((134-141)).”
• Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 (2011, methodology): “Based on its favorable in vitro and in vivo profiles, VX-809 was advanced into clinical studies evaluating the safety and efficacy of VX-809 alone and in combination with VX-770 in patients with CF homozygous for the F508del-CFTR mutation.”